Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
about
Flexibility of the Thrombin-activatable Fibrinolysis Inhibitor Pro-domain Enables Productive Binding of Protein SubstratesQuantitative mass spectrometry analysis using PAcIFIC for the identification of plasma diagnostic biomarkers for abdominal aortic aneurysmA carboxypeptidase inhibitor from the tick Rhipicephalus bursa: isolation, cDNA cloning, recombinant expression, and characterization.Thrombomodulin mutations in atypical hemolytic-uremic syndrome.Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI).Site-specific carboxypeptidase B1 tyrosine nitration and pathophysiological implications following its physical association with nitric oxide synthase-3 in experimental sepsisThrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice are susceptible to intracerebral thrombosis and ischemic stroke.Elevated levels of full-length and thrombin-cleaved osteopontin during acute dengue virus infection are associated with coagulation abnormalities.Thrombin cleavage of osteopontin disrupts a pro-chemotactic sequence for dendritic cells, which is compensated by the release of its pro-chemotactic C-terminal fragmentThrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in miceThrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.Thrombomodulin in the management of acute cholangitis-induced disseminated intravascular coagulation.Thrombin-activatable carboxypeptidase B cleavage of osteopontin regulates neutrophil survival and synoviocyte binding in rheumatoid arthritisKinetics of activated thrombin-activatable fibrinolysis inhibitor (TAFIa)-catalyzed cleavage of C-terminal lysine residues of fibrin degradation products and removal of plasminogen-binding sitesMolecular intercommunication between the complement and coagulation systemsThrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis.Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritisThrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo.Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?Maternal Par4 and platelets contribute to defective placenta formation in mouse embryos lacking thrombomodulin.Osteopontin binding to the alpha 4 integrin requires highest affinity integrin conformation, but is independent of post-translational modifications of osteopontin.Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain.Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in menRegulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).Advances and challenges in hemophilic arthropathy.Complement activation: an emerging player in the pathogenesis of cardiovascular diseaseAntithrombotic Effects of Nur77 and Nor1 Are Mediated Through Upregulating Thrombomodulin Expression in Endothelial Cells.Proteolytic regulatory mechanism of chemerin bioactivity.Insights into thrombin activatable fibrinolysis inhibitor function and regulation.Role of osteopontin in rheumatoid arthritis.Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.Human thrombomodulin regulates complement activation as well as the coagulation cascade in xeno-immune response.The emerging roles of mannose-binding lectin-associated serine proteases (MASPs) in the lectin pathway of complement and beyond.The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complexRegulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and plateletsCarboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.
P2860
Q27664776-BD6BF332-56F6-4F57-B151-374B37F7DCDBQ28478305-B5E4CD71-8926-4181-87A4-838A6BECE13FQ33209290-9ED9C6C0-EC6F-4927-B892-75EE0F8E5FF2Q33385474-A2BE8EE1-6F63-478B-8ACC-ABB0190F2CF4Q33439281-D67BC777-CB66-48EE-997F-742DDBD66679Q33584490-A2AA18A2-46E2-424C-81D9-4C0B03251509Q33640335-F914828F-0F5D-4321-926F-E92C97D0EFB7Q33954396-EA78C8B7-664E-4587-A795-A5457A6F1299Q34245106-CA6A96ED-C4D2-43BD-94D0-9FD964B308F3Q34360710-CBB06908-3472-4A90-8D80-24C4DC45E477Q34391045-35F8C546-B692-4FE6-A6AD-EA56D03BD216Q34612650-E04B5A65-CFF9-4855-986A-7D4D04D245A7Q34932581-F2884C3F-8FA0-4F9A-97BD-51AD26372AEAQ35005687-63BB88E1-3525-4C55-897A-1FEAA083CA80Q35010889-8D082866-4F56-44AB-8A57-FD2F347EE174Q35067949-151372C6-D5A5-4EDC-A9BC-509FB1287F58Q35088199-66F1C58F-17AA-4279-B9E5-0B71E06E31B1Q35116383-42916E78-23F1-4723-A82C-16E1A0A580F2Q35187101-4F6A026C-0858-4282-B4A5-84981891754FQ35642856-047D2335-532F-4AEF-927C-F4591A1E55A9Q36028684-8D47176A-0427-46B8-92C1-C7B164B7EF50Q36579481-1C8778AC-0F64-4B3B-8B87-9961A6947C9CQ36606627-272D7ADD-C890-4349-A389-3C6B7DC748B9Q36787588-B77DA777-62E1-483F-836C-512220266DF8Q37016242-1DC5E150-6D9F-449A-8B09-24C56628573EQ37066273-B133EF7E-2992-48F9-9DF2-3B1519101311Q37207774-959C66F6-3347-4251-A433-E4E81009AD86Q37244922-E8C54511-3C00-4D9D-9773-A246F0EB1BCAQ37279529-3616DC91-6697-4265-A66A-A9D8FE43B58DQ37288362-50DA3C54-78AD-4C36-BF09-E75F8A95D2BBQ37419860-A3218858-DE25-4A19-9BC4-0DA300EEC9F9Q37655187-6C0B9D3F-DFAE-4E6D-8A96-D98AFC472E05Q38117742-CB82F945-9BF6-4235-9C40-88A3EF0CF113Q38243936-FA82C944-C4AD-43D3-B191-D3BCC04E4D68Q38703066-F5B91E3A-DAE3-4217-AC73-EB8C9A6688B3Q38852483-8091BD49-7DA3-44A6-A172-EF0811425898Q38991005-E0C53A8A-B18B-4E86-A91B-3BEC1F3419E1Q39906372-B229839E-7F61-4248-BD1C-59C921A97458Q39916597-9DDF670D-659E-4597-9907-A07A21EF72E5Q41349130-0EF12B79-4FDE-45F2-BEBC-5FEEA8E4A0E5
P2860
Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Thrombin activatable fibrinoly ...... ator of vascular inflammation.
@en
Thrombin activatable fibrinoly ...... ator of vascular inflammation.
@nl
type
label
Thrombin activatable fibrinoly ...... ator of vascular inflammation.
@en
Thrombin activatable fibrinoly ...... ator of vascular inflammation.
@nl
prefLabel
Thrombin activatable fibrinoly ...... ator of vascular inflammation.
@en
Thrombin activatable fibrinoly ...... ator of vascular inflammation.
@nl
P2093
P2860
P356
P1476
Thrombin activatable fibrinoly ...... ator of vascular inflammation.
@en
P2093
Andrew J Patterson
John Morser
Lawrence L K Leung
Mariko Nagashima
Ronald G Pearl
Thomas H Yun
Timothy Myles
Toshihiko Nishimura
P2860
P304
51059-51067
P356
10.1074/JBC.M306977200
P407
P577
2003-10-02T00:00:00Z